CN112522395A - 肺癌甲基化和结直肠癌甲基化判断装置 - Google Patents
肺癌甲基化和结直肠癌甲基化判断装置 Download PDFInfo
- Publication number
- CN112522395A CN112522395A CN201910881816.2A CN201910881816A CN112522395A CN 112522395 A CN112522395 A CN 112522395A CN 201910881816 A CN201910881816 A CN 201910881816A CN 112522395 A CN112522395 A CN 112522395A
- Authority
- CN
- China
- Prior art keywords
- methylation
- value
- positive
- judging
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011987 methylation Effects 0.000 title claims abstract description 243
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 243
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 110
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 110
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 110
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 33
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 101000703741 Homo sapiens Short stature homeobox protein 2 Proteins 0.000 claims abstract description 50
- 238000004364 calculation method Methods 0.000 claims abstract description 26
- 238000001514 detection method Methods 0.000 claims description 26
- 101000632056 Homo sapiens Septin-9 Proteins 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 102100028024 Septin-9 Human genes 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 239000000523 sample Substances 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 20
- 238000003745 diagnosis Methods 0.000 description 11
- 238000013399 early diagnosis Methods 0.000 description 9
- 230000007067 DNA methylation Effects 0.000 description 6
- 102100031976 Short stature homeobox protein 2 Human genes 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 101100477520 Homo sapiens SHOX gene Proteins 0.000 description 3
- 108700025071 Short Stature Homeobox Proteins 0.000 description 3
- 102100029992 Short stature homeobox protein Human genes 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100024154 Cadherin-13 Human genes 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 108010066705 H-cadherin Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
RASSF1A-△Ct1 | 灵敏度 | 特异性 | 约登指数 |
12.970 | 36.2% | 86.7% | 0.362 |
10.515 | 31.7% | 80.5% | 0.381 |
13.035 | 38.1% | 85.4% | 0.41 |
SHOX2-△Ct2 | 灵敏度 | 特异性 | 约登指数 |
9.335 | 75.9% | 81.8% | 0.557 |
9.045 | 74.1% | 84.8% | 0.589 |
9.225 | 75.9% | 84.8% | 0.608 |
灵敏度 | 特异性 | |
SHOX2阳性 | 72.7% | 88.8% |
RASSF1A阳性 | 35.1% | 93.8% |
SHOX2或RASSF1A阳性 | 82.6% | 87.5% |
SEPT9-△Ct3 | 灵敏度 | 特异性 | 约登指数 |
9.489 | 67.7% | 88.8% | 0.478 |
8.966 | 63.1% | 89.8% | 0.509 |
9.153 | 68.3% | 87.5% | 0.538 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910881816.2A CN112522395B (zh) | 2019-09-18 | 2019-09-18 | 肺癌甲基化和结直肠癌甲基化判断装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910881816.2A CN112522395B (zh) | 2019-09-18 | 2019-09-18 | 肺癌甲基化和结直肠癌甲基化判断装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112522395A true CN112522395A (zh) | 2021-03-19 |
CN112522395B CN112522395B (zh) | 2024-04-16 |
Family
ID=74975093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910881816.2A Active CN112522395B (zh) | 2019-09-18 | 2019-09-18 | 肺癌甲基化和结直肠癌甲基化判断装置 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112522395B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774957A (zh) * | 2015-04-24 | 2015-07-15 | 上海透景生命科技股份有限公司 | 诊断人shox2基因和人rassf1a基因甲基化的方法和试剂盒 |
CN107034296A (zh) * | 2017-06-05 | 2017-08-11 | 北京鑫诺美迪基因检测技术有限公司 | 一种用于早期肺癌无创筛查的组合物及其应用 |
WO2019144275A1 (zh) * | 2018-01-23 | 2019-08-01 | 北京艾克伦医疗科技有限公司 | 鉴定肺癌状态的方法和试剂盒 |
CN110079521A (zh) * | 2019-05-06 | 2019-08-02 | 上海埃文生物科技有限公司 | Dna亚硫酸盐转化处理的方法及试剂盒 |
CN113186293A (zh) * | 2021-06-04 | 2021-07-30 | 杭州圣庭医疗科技有限公司 | 一种用于检测肺癌相关基因甲基化的核酸组合物、试剂盒和检测方法 |
-
2019
- 2019-09-18 CN CN201910881816.2A patent/CN112522395B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104774957A (zh) * | 2015-04-24 | 2015-07-15 | 上海透景生命科技股份有限公司 | 诊断人shox2基因和人rassf1a基因甲基化的方法和试剂盒 |
CN107034296A (zh) * | 2017-06-05 | 2017-08-11 | 北京鑫诺美迪基因检测技术有限公司 | 一种用于早期肺癌无创筛查的组合物及其应用 |
WO2019144275A1 (zh) * | 2018-01-23 | 2019-08-01 | 北京艾克伦医疗科技有限公司 | 鉴定肺癌状态的方法和试剂盒 |
CN110079521A (zh) * | 2019-05-06 | 2019-08-02 | 上海埃文生物科技有限公司 | Dna亚硫酸盐转化处理的方法及试剂盒 |
CN113186293A (zh) * | 2021-06-04 | 2021-07-30 | 杭州圣庭医疗科技有限公司 | 一种用于检测肺癌相关基因甲基化的核酸组合物、试剂盒和检测方法 |
Non-Patent Citations (2)
Title |
---|
JUANHONG SHI 等: ""Performance Evaluation of SHOX2 and RASSF1A Methylation for the Aid in Diagnosis of Lung Cancer Based on the Analysis of FFPE Specimen"", 《FRONTIERS IN ONCOLOGY》, vol. 10, pages 1 - 9 * |
张毅敏 等: ""肺泡灌洗液中 SHOX2 和 RASSF1A 基因 甲基化联合检测对肺癌的诊断价值"", 《肿瘤学杂志》, vol. 22, no. 12, pages 1032 - 1036 * |
Also Published As
Publication number | Publication date |
---|---|
CN112522395B (zh) | 2024-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer | |
JP7169002B2 (ja) | 癌の検出のための血漿dna中のサイズ及び数異常の使用 | |
Liang et al. | Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test | |
CN105219844B (zh) | 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型 | |
CN105671181B (zh) | 用于检测肺癌的基因标志物、引物、探针及试剂盒 | |
CN111863250B (zh) | 一种早期乳腺癌的联合诊断模型及系统 | |
EP3249051A1 (en) | Use of methylation sites in y chromosome as prostate cancer diagnosis marker | |
Zeng et al. | Cell-free DNA from bronchoalveolar lavage fluid (BALF): a new liquid biopsy medium for identifying lung cancer | |
US20210404016A1 (en) | Classification of subtypes of kidney tumors using dna methylation | |
CN107435062A (zh) | 甄别肺部微小结节良恶性的外周血基因标志物及其用途 | |
CN111968702B (zh) | 一种基于循环肿瘤dna的恶性肿瘤早期筛查系统 | |
Yu et al. | Urinary and plasma cell-free DNA comparison for lung cancer patients treated with epidermal growth factor receptor—thyroxine kinase inhibitors | |
Eaton et al. | Recall processes for biliary cytology in primary sclerosing cholangitis | |
Zhang et al. | Establishment and evaluation of EGFR mutation prediction model based on tumor markers and CT features in NSCLC | |
CN105907875A (zh) | 一种筛选肾癌外周血miRNA标志物的方法及肾癌标志物miR-378 | |
Lin et al. | A multicenter-retrospective cohort study of chromosome instability in lung cancer: clinical characteristics and prognosis of patients harboring chromosomal instability detected by metagenomic next-generation sequencing | |
CN112522395B (zh) | 肺癌甲基化和结直肠癌甲基化判断装置 | |
Zhang et al. | A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA | |
CN115561468A (zh) | 一种评估患有肿瘤或特定肿瘤风险的方法 | |
Barón et al. | Clinical utility of chromosomal Aneusomy in individuals at high risk of lung Cancer | |
CN108460247B (zh) | 基于kras和ndrg4基因确定结直肠肿瘤细胞的方法和系统 | |
CN108251532B (zh) | 基于ngs技术的粪便dna结直肠肿瘤多基因预测模型 | |
WO2020127629A1 (en) | Identification of global sequence features in whole genome sequence data from circulating nucelic acid | |
CN115472226B (zh) | 建立诊断大肠癌模型的方法、用于分析粪便样本基因的设备和计算机程序 | |
WO2022257955A1 (zh) | 一种前列腺癌早期诊断系统 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231016 Address after: 200120, 3rd Floor, Building 3, No. 412 Huiqing Road, Pudong New Area, Shanghai Applicant after: Shanghai Jiayu Life Technology Co.,Ltd. Address before: 201203 Building 1, No. 115, Lane 572, Bibo Road, Pudong New Area, Shanghai Applicant before: SHANGHAI TELLGEN LIFE SCIENCE CO.,LTD. Applicant before: SHANGHAI TELLGEN DIAGNOSIS TECHNOLOGY CO.,LTD. |
|
TA01 | Transfer of patent application right | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210319 Assignee: SHANGHAI TELLGEN LIFE SCIENCE CO.,LTD. Assignor: Shanghai Jiayu Life Technology Co.,Ltd. Contract record no.: X2023990000988 Denomination of invention: Lung cancer methylation and colorectal cancer methylation detection device License type: Exclusive License Record date: 20231218 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
GR01 | Patent grant | ||
GR01 | Patent grant |